https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-26 / Cancer Immunol. Immunother. 2012 Sep;61(9):1407-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-26 / Cancer Immunol. Immunother. 2012 Sep;61(9):1407-132012-01-26 00:00:002019-02-15 08:48:05Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-17 / Cancer 2012 Sep;118(17):4354-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-17 / Cancer 2012 Sep;118(17):4354-622012-01-17 00:00:002023-03-07 13:04:41HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-10 / JOP 2012 Jan;13(1):45-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-10 / JOP 2012 Jan;13(1):45-532012-01-10 00:00:002012-01-10 00:00:00Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-03 / Scand. J. Gastroenterol. 2012 Mar;47(3):315-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-03 / Scand. J. Gastroenterol. 2012 Mar;47(3):315-242012-01-03 00:00:002019-02-15 08:46:00Immunotherapy for metastatic colorectal cancer: present status and new options
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Curr. Top. Microbiol. Immunol. 2012;351:181-220
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Curr. Top. Microbiol. Immunol. 2012;351:181-2202012-01-01 00:00:002019-02-15 08:49:17The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Methods Mol. Biol. 2012;797:177-204
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Methods Mol. Biol. 2012;797:177-2042012-01-01 00:00:002021-11-15 16:57:22Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Urologe A 2012 Jan;51(1):44-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Urologe A 2012 Jan;51(1):44-92012-01-01 00:00:002019-02-15 08:52:47[Prostate carcinoma: vaccination as a new option for treatment]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / J Immunother 2012 Jan;35(1):54-65
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / J Immunother 2012 Jan;35(1):54-652012-01-01 00:00:002023-03-07 13:05:51A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Apoptosis 2012 Jan;17(1):102-12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Apoptosis 2012 Jan;17(1):102-122012-01-01 00:00:002019-02-15 09:17:18Inhibition of checkpoint kinase 1 abrogates G2/M checkpoint activation and promotes apoptosis under heat stress
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Int J Hyperthermia 2012;28(1):9-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Int J Hyperthermia 2012;28(1):9-182012-01-01 00:00:002019-02-15 09:17:17Effector CD8+ T cell IFN-γ production and cytotoxicity are enhanced by mild hyperthermia
